StockMacro
Menu

Aardvark Therapeutics

$0.92 -78% in 6 monthsMarket cap $20.2M

AARD on XNAS, Health Care, Aardvark Therapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

Shares fell 79% in a month to $0.92 while the company has $60.3M in cash.

  • BadNet loss of $72.8M over the last 12 months
  • BadInsiders sold $395K in 90 days and bought $0

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

Industry
Pharmaceutical preparations (Health Care)
Employees
28
Website
aardvarktherapeutics.com
Listed
Nasdaq, US
Last results
13 Nov 2026
Next results
expected around 22 Mar 2027 (an estimate: a year ago it reported on 23 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $0, net loss $19.2M.
Quarter to 31 Mar 2024: revenue –, net income -$2.2MQuarter to 30 Jun 2024: revenue –, net income -$5.4MQuarter to 30 Sep 2024: revenue –, net income -$4.2MQuarter to 31 Dec 2024: revenue –, net income -$8.8MQuarter to 31 Mar 2025: revenue $0, net income -$9.3MQuarter to 31 Mar 2025: revenue $0, net income -$9.3MQuarter to 30 Jun 2025: revenue $0, net income -$14.4MQuarter to 30 Jun 2025: revenue $0, net income -$14.4MQuarter to 30 Sep 2025: revenue $0, net income -$16.3MQuarter to 30 Sep 2025: revenue $0, net income -$16.3MQuarter to 31 Dec 2025: revenue $0, net income -$17.6MQuarter to 31 Dec 2025: revenue $0, net income -$17.6MQuarter to 31 Mar 2026: revenue $0, net income -$21.6MQuarter to 31 Mar 2026: revenue $0, net income -$21.6MQuarter to 30 Jun 2026: revenue $0, net income -$14.4MQuarter to 30 Jun 2026: revenue $0, net income -$14.4MQuarter to 30 Sep 2026: revenue $0, net income -$19.2MQuarter to 30 Sep 2026: revenue $0, net income -$19.2M
31 Mar 2024RevenueNet incomeNet losstallest bar $21.6M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$0-$19.2M
30 Jun 2026$0-$14.4M
31 Mar 2026$0-$21.6M
31 Dec 2025$0-$17.6M
30 Sep 2025$0-$16.3M
30 Jun 2025$0-$14.4M
31 Mar 2025$0-$9.3M
31 Dec 2024–-$8.8M
30 Sep 2024–-$4.2M
30 Jun 2024–-$5.4M
31 Mar 2024–-$2.2M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$72.8M -$48.8M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$3.34 -$4.30
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -80.9% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – -$45.2M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $60.3M $126.4M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$60.3M (net cash) -$126.4M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $2.63
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 0.35 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Aardvark TherapeuticsAARD (this company) $20.2Mloss–––
TransCode TherapeuticsRNAZ $20.1Mloss–––
Adicet BioACET $20.0Mloss–––
TherapeuticsMDTXMD $19.8M1625.3+34%3.3%
IGC PharmaIGC $19.6Mloss15.6+14%-644%
Edesa BiotechEDSA $19.3Mloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$395K

bought $0, sold $395K

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+7.0%

76 13F filers vs 71

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

44%

9.5M shares held by 13F filers (30 Sep 2026) of 21.9M outstanding (2 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

4.7%

1.0M shares sold short (30 Oct 2026) of 21.9M outstanding (2 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

1.0

1.0M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+88%

553K shares sold short in the report before, 1.0M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

73%

73% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 51%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

4

4 articles in the last 7 days; its usual week has 3 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

1.3×

4 articles in the last 7 days; its usual week has 3.

Price $0.92 on 20 Nov 2026, -90% over 12 months (12-month range $0.91 to $15.82)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders sold a net $250K in the last 12 months (the 12 months before: $23.7M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 1 published in the last 12 months (none in the 12 months before).
Revenue per quarter. Revenue $0 in the latest quarter.
Capital spending per quarter. Capital spending $0 in the latest quarter, -100% on a year earlier.
Institutional holders (13F filers). 76 13F filers reported holding it in the latest 13F quarter, +58% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
8 Oct 20268-K and other filingsDirector or officer change
8 Oct 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
12 Jun 20268-K and other filingsDirector or officer change
12 Jun 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
12 Feb 20268-K and other filingsDirector or officer change
12 Feb 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Feb 2025Sharp changeClustered insider buying: clustered insider buying (4 independent filers, 4 filing(s) in 30 days, value_usd total 23.4M)
6 Feb 20258-K and other filingsRegistered new securities for sale (S-1)
23 Jan 20258-K and other filingsRegistered new securities for sale (S-1)
15 May 20248-K and other filingsPrivate placement of securities (Form D)
Insider net buying (open market)
Month from 1 Feb 2025: $23.4M published
Month from 1 Sep 2025: $306K published
Month from 1 Dec 2025: $145K published
Month from 1 Sep 2026: -$395K published
H-1B/E-3 applications certified
Quarter from 1 Jan 2026: 1 published
Revenue per quarter
Quarter ended 31 Mar 2025: $0; public on 15 May 2025
Quarter ended 30 Jun 2025: $0; public on 14 Aug 2025
Quarter ended 30 Sep 2025: $0; public on 14 Nov 2025
Quarter ended 31 Dec 2025: $0; public on 24 Mar 2026
Quarter ended 31 Mar 2026: $0; public on 8 May 2026
Quarter ended 30 Jun 2026: $0; public on 12 Aug 2026
Quarter ended 30 Sep 2026: $0; public on 14 Nov 2026
Capital spending per quarter
Quarter ended 31 Mar 2024: $5K; public on 15 May 2025
Quarter ended 30 Jun 2024: $93K; public on 14 Aug 2025
Quarter ended 30 Sep 2024: $5K; public on 14 Nov 2025
Quarter ended 31 Dec 2024: $6K; public on 24 Mar 2026
Quarter ended 31 Mar 2025: $0, -100% on a year earlier; public on 15 May 2025
Quarter ended 30 Jun 2025: $91K, -2.2% on a year earlier; public on 14 Aug 2025
Quarter ended 30 Sep 2025: $4K, -20% on a year earlier; public on 14 Nov 2025
Quarter ended 30 Sep 2026: $0, -100% on a year earlier; public on 14 Nov 2026
Institutional holders (13F filers)
31 Mar 2025 report: 27; public on 15 May 2025
30 Jun 2025 report: 33; public on 14 Aug 2025
30 Sep 2025 report: 48; public on 14 Nov 2025
31 Dec 2025 report: 66; public on 17 Feb 2026
31 Mar 2026 report: 75; public on 15 May 2026
30 Jun 2026 report: 71; public on 14 Aug 2026
30 Sep 2026 report: 76; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market selling (USD, Form 4) at $395K (11 Sep 2026), higher than 100% of its own history.
  • Insider net buying (open market): Insiders sold a net $250K in the last 12 months (the 12 months before: $23.7M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 1 published in the last 12 months (none in the 12 months before).
  • Revenue per quarter: Revenue $0 in the latest quarter.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 10 insider trades

Last 90 days: 1 sale, $395K; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
11 Sep 2026Nelson SunSee RemarksSellplanned in advance (10b5-1)76,754$5.15$395KForm 4
12 Dec 2025Tien-Li LeeChief Executive OfficerBuy7,000$14.49$101KForm 4
12 Dec 2025Nelson SunChief Financial OfficerBuy3,000$14.40$43KForm 4
16 Sep 2025Tien-Li LeeChief Executive OfficerBuy10,000$9.66$97KForm 4
12 Sep 2025Tien-Li LeeChief Executive OfficerBuy20,000$8.03$161KForm 4
10 Sep 2025Nelson SunChief Financial OfficerBuy6,000$8.07$48KForm 4
19 Feb 2025Nelson SunChief Financial OfficerBuy10,000$16.00$160KForm 4
19 Feb 2025Decheng Capital Global Life Sciences Fund IV, L.P. and 4 others10% ownerBuy1,250,000$16.00$20.0MForm 4

76 institutions reported shares at the end of Q3 2026, 44% of the shares outstanding; 13 opened a position, 9 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Decheng Capital LLC3.9M17.9%$20.6MNo change
Laurion Capital Management LP1.0M4.73%$5.5MNo change
Citadel Advisors LLC975K4.45%$5.1M-308K-24%
EcoR1 Capital, LLC720K3.29%$3.8M+324K+82%
Vanguard Capital Management LLC558K2.55%$2.9M-4,951-0.9%
ExodusPoint Capital Management, LP316K1.45%$1.7MNew+316K
BlackRock, Inc.195K0.89%$1.0M+7,575+4.0%
Geode Capital Management, LLC139K0.63%$733K-11K-7.2%
Marshall Wace, LLP132K0.60%$697K+113K+593%
Jacobs Levy Equity Management, Inc130K0.59%$686KNew+130K

Company events

All 9 company events

In 12 months: 3 director or officer changes, 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
8 Oct 2026Director or officer change8-K
12 Jun 2026Director or officer change8-K
23 Mar 2026Signed a major agreement8-K
12 Feb 2026Director or officer change8-K
6 Feb 2025Registered new securities for sale (S-1)S-1/A
23 Jan 2025Registered new securities for sale (S-1)S-1
15 May 2024Private placement of securities (Form D)$85.0M sold of $85.0M offeredD
7 Jun 2021Private placement of securities (Form D)$9.1M sold of $30.0M offeredD

The 5 newest of 131 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 8 Oct 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  2. 8 Oct 2026Filings record

    Director or officer change

  3. 12 Jun 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  4. 12 Jun 2026Filings record

    Director or officer change

  5. 12 Feb 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  6. 12 Feb 2026Filings record

    Director or officer change

  7. 13 Dec 2025Insiders record

    Lee Tien-Li (Chief Executive Officer) bought 7,000 shares of AARD ($101,430) (dated 12 Dec 2025)

  8. 13 Dec 2025Insiders record

    Sun Nelson (Chief Financial Officer) bought 3,000 shares of AARD ($43,200) (dated 12 Dec 2025)

  9. 17 Sep 2025Insiders record

    Lee Tien-Li (Chief Executive Officer) bought 10,000 shares of AARD ($96,605) (dated 16 Sep 2025)

  10. 13 Sep 2025Insiders record

    Lee Tien-Li (Chief Executive Officer) bought 20,000 shares of AARD ($160,610) (dated 12 Sep 2025)

  11. 11 Sep 2025Insiders record

    Sun Nelson (Chief Financial Officer) bought 6,000 shares of AARD ($48,420) (dated 10 Sep 2025)

  12. 20 Feb 2025Insiders change

    had 4 insiders buy $23.4M of its shares on the open market within 30 days (4 filings).

    Who bought: Lee Tien-Li, Sun Nelson.

    See the evidence (4 source records)
    Independent buyers
    4
    Purchase filings (Form 4, code P)
    4
    Total bought
    $23.4M
    Window
    21 Jan 2025 to 20 Feb 2025

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  13. 20 Feb 2025Insiders record

    Sun Nelson (Chief Financial Officer) bought 10,000 shares of AARD ($160,000) (dated 19 Feb 2025)

  14. 20 Feb 2025Insiders record

    Decheng Capital Global Life Sciences Fund IV, L.P. (ten percent owner) and 4 other(s) bought 1,250,000 shares of AARD ($20.0M) (dated 19 Feb 2025)

  15. 20 Feb 2025Insiders record

    Lee Tien-Li (Chief Executive Officer) bought 16,542 shares of AARD ($264,672) (dated 19 Feb 2025)

  16. 20 Feb 2025Insiders record

    Chen Bihua (Former 10% Owner) and 1 other(s) bought 187,500 shares of AARD ($3.0M) (dated 19 Feb 2025)

  17. 6 Feb 2025Filings record

    Registered new securities for sale (S-1)

  18. 23 Jan 2025Filings record

    Registered new securities for sale (S-1)

  19. 15 May 2024Filings record

    Private placement of securities (Form D)

  20. 7 Jun 2021Filings record

    Private placement of securities (Form D)

  21. 24 May 2019Filings record

    Private placement of securities (Form D)

Not listed: 33 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001774857
Ticker
AARD
Domain
aardvarktherapeutics.com
Employer name
Aardvark Therapeutics Inc. (1 unverified)
Fein
82-1606367 (1 unverified)
Hq location
CA|SAN DIEGO|92122 (1 unverified)
Name
Aardvark Therapeutics, Inc., Ardia Therapeutics, Inc, Artisan Therapeutics, Inc
  • DOL H-1B labor condition applications and PERM certifications5 data points17 Nov 2025 to 17 Nov 2025
  • SEC Form 13F institutional holdings63 data points31 Mar 2025 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)40 records24 May 2019 to 13 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)153 data points31 Dec 2023 to 2 Nov 2026
  • SEC Form 4 insider transactions10 records, 24 data points19 Feb 2025 to 11 Sep 2026
  • FINRA short interest (twice monthly)125 data points14 Feb 2025 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)892 data points13 Feb 2025 to 20 Nov 2026